Dr. Reddy’s Laboratories has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), a generic equivalent to Extra-Strength Pataday® Once Daily Relief, in the U.S. This antihistamine eye drop provides temporary relief from itchy eyes due to allergens like pollen, ragweed, and animal dander. The launch expands Dr. Reddy’s OTC eye-care portfolio and provides a store-brand alternative in the U.S. market. The product is available in a 2.5 mL bottle.
OTC Eye Solution Launched
Dr. Reddy’s Laboratories announced the launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the U.S. market. This launch was announced on January 14, 2026, and is approved by the U.S. Food and Drug Administration (USFDA).
Product Details
The Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop designed to relieve itchy eyes caused by allergens. It offers relief from irritants such as pollen, ragweed, grass, and animal hair.
Strategic Expansion
This launch expands Dr. Reddy’s presence in the OTC eye-care sector, complementing their existing Olopatadine Hydrochloride Ophthalmic Solution USP offerings (0.2% and 0.1% strengths). The company aims to strengthen its relationships with retail customers by delivering store-brand equivalents of popular OTC brands in the U.S.
Market Context
The Pataday® brand, for which Dr. Reddy’s product is a generic equivalent, had U.S. sales of approximately $69.9 million for the 52 weeks ending December 27, 2025, according to NIQ data.
Source: BSE
